In CAR-T cell therapy, T cells (including both CD4 and CD8 T cells) from cancer patients are transduced ex vivo with retroviral/lentiviral vectors expressing an antibody-based receptor specific for an antigen expressed on the cancer cells. This evidence concerns the gene CD4 and cancer.